DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function

Information source: Philadelphia Veterans Affairs Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Isosorbide Mononitrate, sustained release (Drug); Placebo capsule (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Philadelphia Veterans Affairs Medical Center

Official(s) and/or principal investigator(s):
Julio A Chirinos, MD, PhD, Principal Investigator, Affiliation: Philadelphia VA Medical Center & University of Pennsylvania

Overall contact:
Julio A Chirinos, MD, PhD, Phone: 215-823-5800, Ext: 6791, Email: julio.chirinos@uphs.upenn.edu

Summary

The purpose of this research study is to test whether treatment with isosorbide mononitrate will improve left ventricular hypertrophy ("thickening") which puts people at risk for developing heart failure. Once it develops, heart failure is a very serious condition and thus it is important to find ways to prevent it from happening. The investigators have reasons to believe that dilating the blood vessels with this specific medication will improve the thickening of the heart, which increases the risk of heart failure.

Clinical Details

Official title: Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change in left ventricular mass

Secondary outcome:

Change in extracellular volume fraction

Change in peak myocardial systolic longitudinal strain measured by MRI

Change in peak early diastolic intraventricular pressure gradient measured by MRI

Change in late systolic hypertension derived from pulse wave analysis

Eligibility

Minimum age: 18 Years. Maximum age: 89 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Systolic blood pressure >140 mmHg, diastolic blood pressure > 90 mmHg.

- An elevated left ventricular mass index (defined as >60 g/m1. 7 in women and 80 g/m1. 7

in men) OR LV posterior wall thickness >1. 4 cm documented in a clinically indicated echocardiographic examination or magnetic resonance imaging scan within the previous 12 months.

- Stable medical therapy as defined by: (1)No addition or removal of ACE inhibitors,

angiotensin receptor blockers, beta-blockers, or calcium channel blockers for 30 days. (2)No change in dosage of ACE, angiotensin-receptor blocker, beta-blockers or calcium-channel blockers s of more than 100% for 30 days.

- Current therapy with an ACE inhibitor, hydralazine or a statin, all of which have

been shown to reduce nitrate tolerance. Exclusion Criteria:

- Rhythm other than sinus rhythm (i. e., atrial fibrillation).

- Non-cardiac condition limiting life expectancy to less than one year, per physician

judgment.

- Current or anticipated future need for nitrate therapy.

- Valve disease (> mild aortic or mitral stenosis; > moderate aortic or mitral

regurgitation).

- Hypertrophic cardiomyopathy.

- Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid).

- Pericardial disease.

- Primary pulmonary arteriopathy.

- Have experienced a myocardial infarction or unstable angina, or have undergone

percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at the time of consent.

- Resting heart rate (HR) > 100 bpm.

- A reduced LV ejection fraction (EF<50%).

- Known severe liver disease (AST > 3x normal, alkaline phosphatase or bilirubin > 2x

normal).

- Patients with a clinically indicated stress test demonstrating significant ischemia

within a year of enrollment which was not followed by percutaneous or surgical revascularization.

- Allergy to isosorbide mononitrate.

- Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardenafil or

tadalafil, since the combination of nitrates and phosphodiesterase inhibitors can result in severe hypotension.

- Therapy with rosiglitazone, since this combination is not recommended based on

epidemiologic data suggesting that it may increase the risk of myocardial ischemia.

- Current pregnancy or a positive urine pregnancy test. Women who become pregnant

during the study will be discontinued from the trial.

- Contraindications to a cardiac MRI: (i) Central nervous system aneurysm clips; (ii)

Implanted neural stimulators; (iii) Implanted cardiac pacemaker or defibrillator; (iv) Cochlear implant; (v) Ocular foreign body (e. g. metal shavings); (vi) Other implanted medical devices: (e. g. drug infusion ports); (vii) Insulin pump; (viii) Metal shrapnel or bullet; (ix) Claustrophobia; (x) Extreme obesity rendering the patient unable to fit into narrow-bore scanners; (xi) Unwillingness of the patient to undergo a cardiac MRI. All patients with metallic implants will be individually evaluated prior to MRI.

Locations and Contacts

Julio A Chirinos, MD, PhD, Phone: 215-823-5800, Ext: 6791, Email: julio.chirinos@uphs.upenn.edu

Philadelphia VA Medical Center, Philadelphia, Pennsylvania 19104, United States; Recruiting
Julio A Chirinos, MD, PhD, Phone: 215-200-7779, Email: julio.chirinos@uphs.upenn.edu
Julio A Chirinos, MD, PhD, Principal Investigator
Additional Information

Related publications:

Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician. 2003 Dec 15;68(12):2393-8. Review.

Li H, Wang SX. Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate. J Nephrol. 2011 Mar-Apr;24(2):236-45.

Starting date: August 2013
Last updated: October 27, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017